PODCAST: China’s Burgeoning Debt, and a New Type of China IPO

Illustration of the unbalance of China's debt and GDP

By Doug Young & Rene Vanguestaine

China’s debt-to-GDP ratio swelled to 288% last year, up 13.5 basis points and a huge level by any standard. Is this kind of debt level sustainable, or will something have to give? And a company called Arrivent has just listed in New York, banking on its licensing deal for a made-in-China cancer drug to make its own big money by selling the drug in the U.S. What’s the China risk behind this kind of company?

About China Inc

China Inc by Bamboo Works discusses the latest developments on Chinese companies listed in Hong Kong and the United States to drive informed decision-making for investors and others interested in this dynamic group of companies.

Subscribe to China Inc on your favorite app:

Apple Podcasts Spotify Google Podcasts

,
, , , ,

Related Articles

RELATED ARTICLES

  1. CHINA BULLETIN: Local Governments Crushed by Debt
  2. CHINA BULLETIN: China-U.S. Rapprochement Continues with Xi-Biden Call, Yellen Visit
  3. CHINA BULLETIN: GDP Rebounds, as Putin Comes Calling
  4. CHINA BULLETIN: Economic Growth Target Stays at 5%
  5. CHINA BULLETIN: China Eases Up on Cross-Border Data Requirements
  6. CHINA BULLETIN: Bring on the Equipment Upgrades, Says Beijing
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo File-alt

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

Recent Articles

The loss-making developer of cancer immunotherapies raised just enough financing last year to cross the valuation threshold for a Hong Kong listing.

Sunho Biologics gets green light for downsized IPO

The loss-making developer of cancer immunotherapies raised just enough financing last year to cross the valuation threshold for a Hong Kong listing Key Takeaways: Sunho Biologics has no revenue or…